The Cost of Pharmaceutical Promotion in the US
Author Information
Author(s): Marc-André Gagnon, Joel Lexchin
Primary Institution: Université du Québec à Montréal, York University
Hypothesis
A new estimate of pharmaceutical promotion expenditures is needed to understand the industry's spending compared to research and development.
Conclusion
Pharmaceutical companies spend almost twice as much on promotion as they do on research and development.
Supporting Evidence
- Pharmaceutical companies spent US$33.5 billion on promotion in 2004 according to CAM.
- IMS reported US$27.7 billion for the same year.
- The study found that promotion consumes 24.4% of sales compared to 13.4% for R&D.
Takeaway
Pharmaceutical companies spend a lot of money to promote their drugs, much more than they spend on research to make new ones.
Methodology
The study compared promotional spending estimates from IMS and CAM, using proprietary databases and surveys of physicians.
Potential Biases
Companies may underestimate promotional costs to enhance their public image.
Limitations
The estimates may be incomplete due to unmonitored promotional spending and reliance on self-reported data from companies.
Participant Demographics
The study surveyed a representative sample of 2,000 primary care physicians and 4,800 specialists in the US.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website